Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS??? EQUITY

v3.24.1.1.u2
STOCKHOLDERS’ EQUITY
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

4. STOCKHOLDERS’ EQUITY

 

AT-THE-MARKET OFFERING

 

During the three months ended March 31, 2024, the Company sold an aggregate of 8,177,472 shares of common stock aggregate gross proceeds of $25,651, less issuance costs of $581, for net proceeds of $25,070.

 

COMMON STOCK

 

During the three months ended March 31, 2024, the Company issued an aggregate of 837 shares of common stock for services to an employee with an issuance date fair value of $2.

 

STOCK-BASED COMPENSATION

 

The Company recognized stock-based compensation expense related to common stock, stock options and warrants for the three months ended March 31, 2024 and 2023 of $917 and $7,775, respectively, which is included within compensation expense on the condensed consolidated statements of operations. As of March 31, 2024, there was $3,228 of unrecognized stock-based compensation expense that will be recognized over the weighted average remaining vesting period of 1.3 years.

 

During the three months ended March 31, 2024, the Company granted an aggregate of 141,275 shares of restricted stock with an aggregate grant date fair value of $467 which will be recognized ratably over the vesting terms. The restricted stock have vesting dates ranging from April 15, 2024 to April 15, 2026.